

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

Claim 1. (Withdrawn) A reagent for diagnosis and/or prognostic evaluation of carcinoma, which comprises an anti-P-LAP antibody as an active ingredient.

Claim 2. (Withdrawn) The reagent as claimed in Claim 1, wherein the carcinoma is gynecological carcinoma.

Claim 3. (Withdrawn) The reagent as claimed in Claim 2, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 4. (Withdrawn) The reagent as claimed in Claim 1, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 5. (Withdrawn) The reagent as claimed in Claim 1, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 6. (Withdrawn) A method for determination of P-LAP which is a prognostic factor in carcinoma, which comprises

(a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody, and

(b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody.

Claim 7. (Withdrawn) The method as claimed in Claim 6, wherein the carcinoma is gynecological carcinoma.

Claim 8. (Withdrawn) The method as claimed in Claim 7, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 9. (Withdrawn) The method as claimed in Claim 6, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 10. (Withdrawn) The method as claimed in Claim 6, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 11. (Currently Amended) A method for prognostic evaluation of a P-LAP positive carcinoma, which comprises

- (a) a step of contacting P-LAP positive carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody,
- (b) a step of measuring the intensity of the specific antigen-antibody ~~reaction~~ binding between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and
- (c) a step of correlating the intensity of the specific antigen-antibody ~~reaction~~ binding with prognosis of carcinoma.

Claim 12. (Original) The method as claimed in Claim 11, wherein the carcinoma is gynecological carcinoma.

Claim 13. (Original) The method as claimed in Claim 12, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 14. (Previously Presented) The method as claimed in Claim 11, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 15. (Previously Presented) The method as claimed in Claim 11, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 16. (Withdrawn) An immunoassay kit for determination of the amount of P-LAP present in carcinoma tissues obtained from carcinoma patients, which comprises an anti-P-LAP antibody and a marker enzyme for determination of the amount of the P-LAP bound to the anti-P-LAP antibody.

Claim 17. (New) A method for prognostic evaluation of a P-LAP positive carcinoma in a patient, comprising:

- (a) contacting P-LAP positive carcinoma tissues obtained from said patient with an anti-P-LAP antibody,
- (b) measuring the intensity of the specific antigen-antibody binding between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and
- (c) correlating the intensity of the specific antigen-antibody binding with a ten-year disease-free survival rate (DFS) of said patient.